Common Contracts
6 similar Letter Agreement contracts by Caribou Biosciences, Inc.
Zone III Healthcare Holdings, LLC c/o Farallon Capital Management, L.L.C. One Maritime Plaza, Suite 2100 San Francisco, CA 94111 Attn: Philip Dreyfuss Re: Participation RightsLetter Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) memorializes the agreement and understanding between Zone III Healthcare Holdings, LLC (“Investor”), on the one hand, and Caribou Biosciences, Inc., a Delaware corporation (the “Company”), on the other hand, regarding the Company’s grant to Investor of the right to participate in the Company’s future initial public offering of its equity securities on the terms, and subject to the conditions, set forth below.
Ridgeback Capital Investments LP Miami Beach, FL 33139 Attn: Wayne Holman, M.D. Re: Participation RightsLetter Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) memorializes the agreement and understanding between Ridgeback Capital Investments LP (“Investor”), on the one hand, and Caribou Biosciences, Inc., a Delaware corporation (the “Company”), on the other hand, regarding the Company’s grant to Investor of the right to participate in the Company’s future initial public offering of its equity securities on the terms, and subject to the conditions, set forth below.
PFM Health Sciences, LP San Francisco, CA 94111 Attn: Yuan DuBord Re: Participation RightsLetter Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) memorializes the agreement and understanding between PFM Health Sciences, LP (“Investor”), on the one hand, and Caribou Biosciences, Inc., a Delaware corporation (the “Company”), on the other hand, regarding the Company’s grant to Investor of the right to participate in the Company’s future initial public offering of its equity securities on the terms, and subject to the conditions, set forth below.
Ridgeback Capital Investments LP Miami Beach, FL 33139 Attn: Wayne Holman, M.D. Re: Participation RightsLetter Agreement • May 7th, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) memorializes the agreement and understanding between Ridgeback Capital Investments LP (“Investor”), on the one hand, and Caribou Biosciences, Inc., a Delaware corporation (the “Company”), on the other hand, regarding the Company’s grant to Investor of the right to participate in the Company’s future initial public offering of its equity securities on the terms, and subject to the conditions, set forth below.
PFM Health Sciences, LP San Francisco, CA 94111 Attn: Yuan DuBord Re: Participation RightsLetter Agreement • May 7th, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) memorializes the agreement and understanding between PFM Health Sciences, LP (“Investor”), on the one hand, and Caribou Biosciences, Inc., a Delaware corporation (the “Company”), on the other hand, regarding the Company’s grant to Investor of the right to participate in the Company’s future initial public offering of its equity securities on the terms, and subject to the conditions, set forth below.
Zone III Healthcare Holdings, LLC c/o Farallon Capital Management, L.L.C. One Maritime Plaza, Suite 2100 San Francisco, CA 94111 Attn: Philip Dreyfuss Re: Participation RightsLetter Agreement • May 7th, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) memorializes the agreement and understanding between Zone III Healthcare Holdings, LLC (“Investor”), on the one hand, and Caribou Biosciences, Inc., a Delaware corporation (the “Company”), on the other hand, regarding the Company’s grant to Investor of the right to participate in the Company’s future initial public offering of its equity securities on the terms, and subject to the conditions, set forth below.
